Europe
The new research hub will be called the London Discovery Research Centre and is expected to open by 2025.
Together the two companies will scour comprehensive medical and molecular data sets of thousands of chronic kidney disease patients to identify and then develop possible drugs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.
It was a very busy week for clinical trial updates. Here’s a look.
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the vaccine should it be approved, as well as a late-stage efficacy study in that country.
Niclosamide is an oral anthelminthic drug. It was first approved by the U.S. Food and Drug Administration (FDA) in 1982 and is included in the World Health Organization (WHO)’s list of essential medicines.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
PRESS RELEASES